ES2168006T3 - Factor neurotrofico ciliar modificado, metodo de fabricacion y metodos de utilizacion. - Google Patents
Factor neurotrofico ciliar modificado, metodo de fabricacion y metodos de utilizacion.Info
- Publication number
- ES2168006T3 ES2168006T3 ES99911020T ES99911020T ES2168006T3 ES 2168006 T3 ES2168006 T3 ES 2168006T3 ES 99911020 T ES99911020 T ES 99911020T ES 99911020 T ES99911020 T ES 99911020T ES 2168006 T3 ES2168006 T3 ES 2168006T3
- Authority
- ES
- Spain
- Prior art keywords
- modified
- neurotrophic factor
- manufacturing
- use methods
- ciliar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Food Science & Technology (AREA)
- Neurosurgery (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
Abstract
Un factor neurotrófio ciliar humano modificado, con la modificación Cys17!Ala, Gln63!Arg, y una deleción de los 15 restos de aminoácidos terminales.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/031,693 US6472178B1 (en) | 1998-02-27 | 1998-02-27 | Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2168006T3 true ES2168006T3 (es) | 2002-05-16 |
Family
ID=21860892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES99911020T Expired - Lifetime ES2168006T3 (es) | 1998-02-27 | 1999-02-26 | Factor neurotrofico ciliar modificado, metodo de fabricacion y metodos de utilizacion. |
Country Status (14)
Country | Link |
---|---|
US (4) | US6472178B1 (es) |
EP (1) | EP1056856B1 (es) |
JP (1) | JP4330796B2 (es) |
AT (1) | ATE212375T1 (es) |
AU (1) | AU749660B2 (es) |
CA (1) | CA2320402C (es) |
DE (1) | DE69900816T2 (es) |
DK (1) | DK1056856T3 (es) |
ES (1) | ES2168006T3 (es) |
HK (1) | HK1033336A1 (es) |
IL (2) | IL137858A0 (es) |
NZ (1) | NZ506267A (es) |
PT (1) | PT1056856E (es) |
WO (1) | WO1999043813A1 (es) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040120891A1 (en) * | 1998-12-21 | 2004-06-24 | Craig Hill | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
JP2003507393A (ja) * | 1999-08-13 | 2003-02-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 改変された毛様体神経栄養因子、それらを作製する方法およびそれらの使用方法 |
US7442370B2 (en) | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
CN1500095B (zh) * | 2001-02-01 | 2010-06-16 | 比奥根艾迪克Ma公司 | 神经胚活素的多聚体偶联物及其应用方法 |
EP1234583A1 (en) * | 2001-02-23 | 2002-08-28 | F. Hoffmann-La Roche Ag | PEG-conjugates of HGF-NK4 |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US20050064555A1 (en) * | 2003-07-09 | 2005-03-24 | Xencor, Inc. | Ciliary neurotrophic factor variants |
JP4765627B2 (ja) | 2003-09-22 | 2011-09-07 | Msd株式会社 | 新規ピペリジン誘導体 |
EP1734963A4 (en) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER |
WO2006017156A2 (en) * | 2004-07-09 | 2006-02-16 | Regeneron Pharmaceuticals, Inc. | Methods for identifying a candidate for treatment of obesity |
CA2577060A1 (en) | 2004-08-13 | 2006-02-23 | Amgen Inc. | Substituted benzofused heterocycles |
KR101241551B1 (ko) | 2004-08-19 | 2013-03-11 | 바이오겐 아이덱 엠에이 인코포레이티드 | 전환 성장 인자 베타 패밀리 단백질의 리폴딩 |
EP2127676A3 (en) | 2004-11-01 | 2013-09-04 | Amylin Pharmaceuticals, LLC | Treatment of obesity and related disorders |
GB0425625D0 (en) * | 2004-11-22 | 2004-12-22 | Royal College Of Surgeons Ie | Treatment of disease |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
RU2417985C2 (ru) | 2005-05-30 | 2011-05-10 | Баниу Фармасьютикал Ко., Лтд. | Новые производные пиперидина |
JPWO2007018248A1 (ja) | 2005-08-10 | 2009-02-19 | 萬有製薬株式会社 | ピリドン化合物 |
JPWO2007024004A1 (ja) | 2005-08-24 | 2009-03-05 | 萬有製薬株式会社 | フェニルピリドン誘導体 |
EP1939194A4 (en) | 2005-09-07 | 2010-12-08 | Banyu Pharma Co Ltd | AROMATIC SUBSTITUTED BICYLIC PYRIDONE DERIVATIVE |
CA2624030A1 (en) | 2005-09-29 | 2007-04-12 | Tianying Jian | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
CA2625416A1 (en) | 2005-10-21 | 2007-04-26 | Novartis Ag | Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent |
EP1944301A4 (en) | 2005-10-27 | 2012-01-04 | Msd Kk | NEW BENZOXATHIIN DERIVATIVES |
US8158791B2 (en) | 2005-11-10 | 2012-04-17 | Msd K.K. | Aza-substituted spiro derivatives |
TWI501774B (zh) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
EP2946778A1 (en) | 2006-09-22 | 2015-11-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
CA2664358A1 (en) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | Diarylketimine derivative |
US8592374B2 (en) * | 2007-03-16 | 2013-11-26 | Research Foundation For Mental Hygiene, Inc. | Neurotrophic peptides |
US8796214B2 (en) * | 2007-03-16 | 2014-08-05 | Research Foundation For Mental Hygiene, Inc. | Neurotrophic peptides |
US8796215B2 (en) * | 2007-03-16 | 2014-08-05 | Research Foundation For Mental Hygiene, Inc. | Neurotrophic peptides |
EP2009103A1 (en) * | 2007-03-16 | 2008-12-31 | Ebewe Pharma Ges.m.b.H. Nfg. KG | Neurotrophic peptides |
AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
NZ580947A (en) | 2007-05-01 | 2012-05-25 | Biogen Idec Inc | Compositions and methods for increasing vascularization |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
DK2170930T3 (da) | 2007-06-04 | 2012-11-05 | Synergy Pharmaceuticals Inc | Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme |
JPWO2009110510A1 (ja) | 2008-03-06 | 2011-07-14 | Msd株式会社 | アルキルアミノピリジン誘導体 |
AU2009229860A1 (en) | 2008-03-28 | 2009-10-01 | Msd K.K. | Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor |
JP2011522828A (ja) | 2008-06-04 | 2011-08-04 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
JPWO2009154132A1 (ja) | 2008-06-19 | 2011-12-01 | Msd株式会社 | スピロジアミン−ジアリールケトオキシム誘導体 |
ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
AU2009277736A1 (en) | 2008-07-30 | 2010-02-04 | Banyu Pharmaceutical Co., Ltd. | (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
AU2009307884B2 (en) | 2008-10-22 | 2014-07-31 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
WO2010075068A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
US8796258B2 (en) | 2011-02-25 | 2014-08-05 | Merck Sharp & Dohme Corp. | Cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
JP2016516004A (ja) | 2013-02-22 | 2016-06-02 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病二環式化合物 |
EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
KR102272746B1 (ko) | 2013-06-05 | 2021-07-08 | 보슈 헬스 아일랜드 리미티드 | 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법 |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
DK3186242T3 (da) | 2014-08-29 | 2021-12-20 | Tes Pharma S R L | Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere |
EP3526199B1 (en) | 2016-10-14 | 2022-04-13 | Tes Pharma S.r.l. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | ANTIDIABETIC HETEROCYCLIC COMPOUNDS |
EP3558298A4 (en) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | ANTIDIABETIC SPIROCHROMAN COMPOUNDS |
EP3823674A4 (en) | 2018-07-18 | 2022-12-28 | Manzanita Pharmaceuticals, Inc. | CONJUGATES FOR DELIVERING AN ANTI-CANCER AGENT TO NERVE CELLS, METHODS OF USE AND METHODS OF PRODUCTION THEREOF |
AR117122A1 (es) | 2018-11-20 | 2021-07-14 | Tes Pharma S R L | INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE903130A1 (en) | 1989-09-15 | 1991-03-27 | Regeneron Pharma | Ciliary neurotrophic factor |
KR910016921A (ko) | 1990-03-14 | 1991-11-05 | 파디아 에스. 피. 에이 | 인간의 모양체 신경원영양 인자, 그를 코딩하는 dna 서열 및 재조합 기술에 의한 그의 제조방법 |
IL98304A (en) | 1990-06-01 | 2008-08-07 | Regeneron Pharma | The ciliary neurotrophic factor receptor |
AU2925392A (en) * | 1991-11-11 | 1993-06-15 | Fidia S.P.A. | Synthesis and purification of truncated and mutein forms of human ciliary neuronotrophic factor |
WO1994008026A1 (en) * | 1992-09-25 | 1994-04-14 | Rhone-Poulenc Rorer S.A. | Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain |
US5349056A (en) * | 1992-10-09 | 1994-09-20 | Regeneron Pharmaceuticals | Modified ciliary neurotrophic factors |
AU7204996A (en) * | 1995-10-02 | 1997-04-28 | Cytotherapeutics, Inc. | Method for treating amyotrophic lateral sclerosis |
IT1288388B1 (it) | 1996-11-19 | 1998-09-22 | Angeletti P Ist Richerche Bio | Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia |
KR20000070357A (ko) | 1997-01-23 | 2000-11-25 | 다께우찌 마사야쓰 | 당뇨병 치료제 |
-
1998
- 1998-02-27 US US09/031,693 patent/US6472178B1/en not_active Expired - Lifetime
-
1999
- 1999-02-26 NZ NZ506267A patent/NZ506267A/xx not_active IP Right Cessation
- 1999-02-26 ES ES99911020T patent/ES2168006T3/es not_active Expired - Lifetime
- 1999-02-26 EP EP99911020A patent/EP1056856B1/en not_active Expired - Lifetime
- 1999-02-26 DE DE69900816T patent/DE69900816T2/de not_active Expired - Lifetime
- 1999-02-26 JP JP2000533553A patent/JP4330796B2/ja not_active Expired - Lifetime
- 1999-02-26 AT AT99911020T patent/ATE212375T1/de active
- 1999-02-26 AU AU29763/99A patent/AU749660B2/en not_active Expired
- 1999-02-26 CA CA2320402A patent/CA2320402C/en not_active Expired - Lifetime
- 1999-02-26 WO PCT/US1999/004430 patent/WO1999043813A1/en active IP Right Grant
- 1999-02-26 DK DK99911020T patent/DK1056856T3/da active
- 1999-02-26 IL IL13785899A patent/IL137858A0/xx active IP Right Grant
- 1999-02-26 PT PT99911020T patent/PT1056856E/pt unknown
-
2000
- 2000-05-24 US US09/577,468 patent/US6767894B1/en not_active Expired - Lifetime
- 2000-08-14 IL IL137858A patent/IL137858A/en not_active IP Right Cessation
-
2001
- 2001-01-25 US US09/770,361 patent/US20020123462A1/en not_active Abandoned
- 2001-05-19 HK HK01103460A patent/HK1033336A1/xx not_active IP Right Cessation
-
2002
- 2002-10-28 US US10/281,643 patent/US7119066B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
NZ506267A (en) | 2003-04-29 |
JP4330796B2 (ja) | 2009-09-16 |
PT1056856E (pt) | 2002-07-31 |
ATE212375T1 (de) | 2002-02-15 |
DE69900816D1 (de) | 2002-03-14 |
HK1033336A1 (en) | 2001-08-24 |
US20030144199A1 (en) | 2003-07-31 |
US7119066B2 (en) | 2006-10-10 |
AU2976399A (en) | 1999-09-15 |
CA2320402A1 (en) | 1999-09-02 |
WO1999043813A1 (en) | 1999-09-02 |
DK1056856T3 (da) | 2002-05-06 |
IL137858A (en) | 2008-04-13 |
JP2002504370A (ja) | 2002-02-12 |
US6767894B1 (en) | 2004-07-27 |
IL137858A0 (en) | 2001-10-31 |
US6472178B1 (en) | 2002-10-29 |
US20020123462A1 (en) | 2002-09-05 |
CA2320402C (en) | 2010-10-12 |
EP1056856A1 (en) | 2000-12-06 |
DE69900816T2 (de) | 2002-08-29 |
EP1056856B1 (en) | 2002-01-23 |
AU749660B2 (en) | 2002-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2168006T3 (es) | Factor neurotrofico ciliar modificado, metodo de fabricacion y metodos de utilizacion. | |
ATE186305T1 (de) | Perfluoroalkyll ketone, inhibitoren von elastase und prozess zur deren herstellung | |
DE69021153D1 (de) | Medizinisches Ventil und Herstellungsverfahren, Katheter und Ventil sowie Kathetereinheit. | |
DE69527783D1 (de) | System für die optimierung des kontinuierlichen, positiven atemwegdrucks zur behandlung des atemstillstandes im schlaf bei verlegten atemwegen | |
DE68900371D1 (de) | Textile struktur zur herstellung von schichtstoffen und schichtformteile, die diese struktur enthalten. | |
NZ516349A (en) | Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease | |
ATE438630T1 (de) | 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten | |
DE69901177D1 (de) | Platinkomplex, dessen herstellung und dessen therapeutische verwendung | |
IT1305313B1 (it) | 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1. | |
ATE307203T1 (de) | Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma | |
IL139616A0 (en) | Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating, diseases caused by deficiencies thereof | |
TR200200278T2 (tr) | Kalsilitik bileşimler | |
NO984572L (no) | Anvendelse av 2,5-dihydroksybenzensulfonderivater for fremstilling av legemidler ment for normalisering av den endoteliale funksjon, for behandling av seksuell dysfunksjon og vaskulµre komplikasjoner i diabetes, sÕvel som vaskulµre lidelser av e | |
AU8423401A (en) | The treatment of inflammatory disorders | |
HK1043367A1 (en) | Benzoylguanidine derivatives with advantageous properties, method for producing them and their use in the production of medicaments. | |
WO2003028536A3 (en) | Methods for diagnosing and treating heart disease | |
NZ514691A (en) | Method to type prion proteins | |
HUP0203057A2 (hu) | Módosított ciliáris nerotróf faktor, ennek előállítási és használati módszere | |
WO2001089550A3 (en) | Use of ciliary neurotrophic factor | |
DE69906680D1 (de) | Citronnellyl- und/oder dihydrocitronellyllactate, ihre herstellung und ihre anwendung | |
DE3870912D1 (de) | 4,4'-(perfluorisopropyliden)dicyclohexanol, dessen abkoemmling und verfahren zur herstellung davon. | |
DE69023331D1 (de) | Behandeltes hämoglobin und dessen herstellung. | |
HK1027825A1 (en) | Use of arylguanidinium xanthogenates as vulcanization accelerators and process for the production thereof. | |
WO2002004636A8 (en) | NOVEL α-CATENIN EXPRESSED IN HEART AND TESTIS | |
NL1015302A1 (nl) | Werkwijze voor de productie van 2,3-dimethylbuteen-1 en 2,3-dimethylbuteen-2. |